To evaluate the ability of ravulizumab to reduce proteinuria in adults with IgAN
Access to the investigational medication (ravulizumab) will be available to participants following the double-blinded portion of the trial.
Adults with biopsy proven IgAN (immunoglobulin A nephropathy) Documentation of IgAN diagnosis established on kidney biopsy obtained any time prior to or during the Screening Period (Section 8.1.5). UPCR ≥ 0.75 g/g or UP ≥1 g/day from the mean of two 24-hour urine collections during Screening as described in Section 8.2.1. Estimated GFR ≥ 30 mL/min/1.73 m2 at Screening. Exploratory Cohort: eGFR 20-29 mL/min/1.73 m2 at Screening. A kidney biopsy is required within 6 months prior to Screening or during the Screening Period. Kidney biopsy report must demonstrate < 75% each of interstitial fibrosis, tubular atrophy, and glomerular sclerosis. Presence of hematuria as defined by a positive result on urine dipstick for blood or ≥ 5 red blood cells (RBCs)/high power field microscopy on urine sediment during or within 3 months of Screening
Principal Investigator